Home About the Department Graduate Studies Undergraduate Studies Faculty Facilities and Staff Events Hot Links Contact Us

Jennifer V. Hines
Biochemistry Research Facility
740-593-0148 (Fax)

Ph.D., University of Michigan

Chemical Biology, Molecular Biology, Medicinal Chemistry


The focus of our research group is RNA drug discovery. We employ an interdisciplinary approach to developing RNA-targeted medicinal agents that could potentially treat diseases such as AIDS, multidrug resistant bacterial infections, and cancer. RNA plays a critical role in viral replication, bacterial regulation and cancer biogenesis. By targeting key RNA-mediated regulatory processes for these diseases we hope to ultimately develop novel medicinal agents. Through a combination of chemical, molecular, and structural biology studies we are determining the structure-function relationships of medicinally relevant RNA targets and the structure-activity relationships of small molecule ligands that bind the RNA. We utilize a variety of approaches ranging from biophysical (fluorescence, UV, NMR) to bioinformatics, computational and molecular biology techniques. Our goal is to gain an in-depth understanding of the factors that govern molecular recognition of RNA by small molecules and to use this knowledge in the development of novel medicinal agents.

Selected Publications

Electrophoretic Mobility Shift Assay of RNA-RNA Complexes, Anupam, R., Zhou, S., Hines, J. V., Methods in Molecular Biology Springer Protocols (Humana Press), 2015, 1240, 153-164.

Fluorescence anisotropy: Analysis of tRNA binding to the T box riboswitch antiterminator RNA, Zhou, S., Anupam, R., Hines, J. V., Methods in Molecular Biology Springer Protocols (Humana Press), 2015, 1240, 143-152.

Fluorescence assays for monitoring RNA-ligand interactions and riboswitch-targeted drug discovery screening, Liu, J., Zeng, C., Zhou, S., Hines, J. V., Methods in Enzymology (Elsevier), 2015, 550, 363-383.

Factors that influence T box riboswitch efficacy and tRNA affinity, Zeng, C., Zhou, S., Bergmeier, S.C., Hines, J.V., Bioorg. Med. Chem., 2015, in press DOI:10.1016/j.bmc.2015.07.018.

Identification of spermidine binding site in T box riboswitch antiterminator RNA, Liu, J. Zeng, C., Hogan, V., Zhou, S., Monwar, Md.M., Hines, J.V., Chem. Biol. Drug Design, 2015, in press.

A small molecule inhibitor of glucose transporter 1 (Glut1) down-regulates glycolysis, induces cell cycle arrest, and inhibits cancer cell growth in vitro and in vivo, Y. Liu, Y. Cao, W. Zhang, S. Bergmeier, Y. Qian, H. Akbar, R. Colvin, J. Ding, L. Tong, S. Wu, J. Hines, and X. Chen Mol. Cancer Ther, 2012, 11, 1672-1682.

Fused ring aziridines as a facile entry into triazole fused tricyclic and bicyclic heterocycles, F. Fang, M. Vogel, J.V. Hines, S.C. Bergmeier Org. Biomol. Chemistry, 2012, 10, 3080-3091.

A synthesis of 1,4-disubstituted Imidazolidin-2-ones from fused-ring aziridines, I.W. Maciagiewicz, F. Fang, D.A. Roberts, S. Zhou, J.V. Hines, S.C. Bergmeier Synthesis, 2012, 44, 551-560.

Characterization of a 1,4-disubstituted 1,2,3-triazole binding to T box antiterminator RNA, S. Zhou, J.A. Means, G. Acquaah-Harrison, S.C. Bergmeier, J.V. Hines Bioorg. Med. Chem, 2012, 20, 1298-1302.

Ligand-induced changes in T box antiterminator RNA stability, S. Zhou, G. Acquaah-Harrision, K.D. Jack, S.C. Bergmeier, J.V. Hines. Chem. Biol. Drug Design, 2012, 79, 202-208.

Anisotropy studies of tRNA - T box antiterminator RNA complex in the presence of 1,4-disubstituted 1,2,3-triazoles, S. Zhou, G. Acquaah-Harrison, S.C. Bergmeier, J.V. Hines Bioorg. Med. Chem. Letters, 2011, In press

Interfacing medicinal chemistry with structural bioinformatics: Implications for T box riboswitch RNA drug discovery, F. Jentzsh, J.V. Hines BMC Bioinformatics , (GLBIO 2011 Special Issue) 2011, 13 (Suppl. 2), S5-S10.

Library of 1,4-Disubstituted 1,2,3-Triazole Analogs of Oxazolidinone RNA-Binding Agents, G. Acquaah-Harrison, S. Zhou, J.V. Hines, S.C. Bergmeier J. Comb. Chem. 2010, 12, 491-496.

Fluorescence probing of T box antiterminator RNA: Insights into riboswitch discernment of the tRNA discriminator base, John A. Means, Crystal M. Simson, Shu Zhou, Aaron A. Rachford, Jeffrey J. Rack, J.V. Hines Biochem. Biophys. Res. Commun., 2009, 389, 616-621.

T box transcription antitermination riboswitch: Influence of nucleotide sequence and orientation on tRNA binding by the antiterminator element, Hamid Fauzi, Akwasi Agyeman, J. V. Hines BBA-Gene Regulatory Mechanisms 1789 2009, 185-191.

4,5-Disubstituted Oxazolidinones: High affinity molecular effectors of RNA function, R. Anupam, S. C. Bergmeier, N. J. Green, F. J. Grundy, T. M. Henkin, J. A. Means, A. Nayek, J. V. Hines, Bioorg. Med. Chem. Lett., 2008, 18, 3541-3544 (DOI:10.1016/j.bmcl.2008.05.015)

Characterizing riboswitch function: Identification of Mg2+ binding site in T box antiterminator RNA, K.D. Jack, J.A. Means, J.V. Hines, Biochem. Biophy. Res. Commun., 2008, 370, 306-310

Identification of neomycin B-binding site in T box antiterminator model RNA, R. Anupam, L. Denapoli, A. Muchenditsi, J. V. Hines, Bioorg. Med. Chem., 2008, 16, 4466-4470

T box riboswitch antiterminator affinity modulated by tRNA structural elements, J. A. Means, S. Wolf, A. Agyeman, J. S. Burton, C.M. Simson, J. V. Hines, Chem. Biol. Drug Des., 2007, 69, 139-145.

Structure activity studies of oxazolidinone analogs as RNA-binding agents, J. Means, S. Katz, A. Nayek, R.Anupam, J. V. Hines, S. C. Bergmeier, Bioorg. Med. Chem. Letters, 2006, 16, 3600-3604.